On July 10, 2026, the company received notice from Nasdaq that, following a director's departure after the July 8, 2026 annual meeting, it no longer complies with Nasdaq Listing Rule 5605 regarding independent directors and audit committee composition. Nasdaq granted a cure period until the earlier of the next annual meeting or July 9, 2027, or by January 5, 2027 if the next annual meeting occurs before that date. The notice has no immediate effect on the Nasdaq listing.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.